HP518 - Dose expansion
Phase 2Small molecule
HP518 - Dose expansion is one of 7 small molecule programs targeting Tumor. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Tumor
#DrugCompanyPhaseTrials
1Giapreza
LLa Jolla Pharmaceutical Company
Phase 2
MRI Contrast-Enhancing Agents
SanofiPhase 1
HP518 - Dose expansion
HHinova Pharmaceuticals Aus Pty Ltd
Phase 2
ASK120067
JJiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
ASKC202
JJiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
STR-P004
SStarna Therapeutics
Preclinical
OBX-115
OObsidian Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HP518 - Dose expansion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details